Comparison of DSCT With IB-IVUS and Angiography in the Assessment of Coronary Artery Disease
NCT ID: NCT00622167
Last Updated: 2012-02-03
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
24 participants
INTERVENTIONAL
2008-01-31
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Cardiac Computed Tomography and Vasodilator Stress Magnetic Resonance Imaging Perfusion in Patients With Prior Equivocal Stress Test for Detection of Coronary Artery Disease
NCT00929227
PET/CT Study in the Diagnosis of Coronary Plaque
NCT00850473
Comparison of Coronary CT With IVUS in Heart Transplant Population
NCT00589524
Combined Use of Coronary MDCTA, Coronary Doppler Ultrasonography and PET Perfusion in Diagnosing Coronary Artery Disease
NCT00627172
Integrated Informatics-imaging Approaches to Cardiovascular Disease.
NCT06718465
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To compare with contrast angiography, the ability of DSCT to detect and quantify coronary artery stenoses.
2. To compare with gray-scale IVUS, the ability of DSCT to quantify plaque cross-sectional diameter \& area measurements \& plaque volume.
3. To evaluate the ability of DSCT to assess plaque morphology and quantify plaque components as compared to gray-scale and IB-IVUS.
4. To evaluate the ability of DSCT to identify \& measure lesion remodeling compared to gray-scale IVUS.
5. To determine if pre-PCI evaluation of coronary plaque morphology by IB-IVUS can a) predict procedural success as assessed by adequate stent strut apposition and expansion and b) peri-procedural myocardial necrosis as measured by biomarker elevation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
All patients will receive integrated backscatter IVUS and dual source CT.
Integrated Backscatter IVUS
All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
Dual Source Computed Tomography
All subjects have DSCT and IBIVUS imaging
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Integrated Backscatter IVUS
All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
Dual Source Computed Tomography
All subjects have DSCT and IBIVUS imaging
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \> / = 18 years of age
* Scheduled for coronary angiography
Exclusion Criteria
* Current congestive heart failure
* Current cardiogenic shock
* Unstable clinical condition
* Known cardiomyopathy (EF \< 30%)
* Creatinine \>1.5 mg/dL
* Definite allergy to iodinated contrast media
* Current participation in an investigational drug or device research study
* HR \> 65 and contraindications to the administration of beta blockers
* PCI of native coronary vessel not performed
* Left main stenosis \> 50%
* Any vessel contraindicated for IVUS imaging
* Any lesion contraindicated for IVUS imaging
* Inability to pass IVUS catheter
* PCI of bifurcation lesion
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ik-Kyung Jang, MD, PhD
Professor of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ik-Kyung Jang, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Massachusetts General Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007P001842
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.